OncLive TV

Stacy Tessler Lindau, MD, MA, discusses potential next steps for the Bionic Breast project.

Joseph Dominic Femino, MD, discusses the lack of adjuvant options for chondrosarcoma and the promise of IDH inhibitors like ivosidenib.

Sonali M. Smith, MD, discusses efforts to translate benefit with CAR T-cell therapy from hematologic malignancies to the solid tumor space.

Stacy Tessler Lindau, MD, MA, discusses which patients would be strong fits for the Bionic Breast project.

Experts preview key bladder, kidney, and prostate cancer trials to watch at the 2026 Genitourinary Cancers Symposium.

Joseph Dominic Femino, MD, discusses breakthroughs in limb salvage surgery, including innovative ways to reconstruct bone and joints after resection.

Christopher Lieu, MD, discusses clinical objectives for third-line mCRC management and patient-specific factors guiding therapeutic strategy.

Stacy Tessler Lindau, MD, MA, discusses the design of the Bionic Breast project at University of Chicago.

Martha Welman, MD, discusses several personalized health care disparity interventions that have been shown to increase access to breast cancer screening.

Martha Welman, MD, discusses findings from a study of strategic screening initiatives aimed at reducing breast cancer diagnostic disparities.

Stacy Tessler Lindau, MD, MA, discusses the primary goals of the Bionic Breast project.

Benjamin A. Weinberg, MD, FACP, discusses how biomarker status guides third-line treatment selection in mCRC.

Stacy Tessler Lindau, MD, MA, outlines prior research that informed the initiation of the Bionic Breast project at University of Chicago.

Martha Welman, MD, discusses patient navigation interventions aiming to address unmet needs in the breast cancer screening and diagnosis pathway.

Robert Neff, MD, discusses ongoing research in cervical cancer screening.

Vikram C. Gorantla, MD, discusses future directions for sequencing available therapies for patients with breast cancer who develop brain metastases.

Stacy Tessler Lindau, MD, MA, discusses the unmet need of restoring breast sensation following mastectomy.

Stacy Tessler Lindau, MD, MA, discusses the background of the Bionic Breast program at University of Chicago.

Vikram C. Gorantla, MD, discusses real-world treatment patterns with T-DXd vs tucatinib-based therapy in HER2-positive breast cancer with brain metastases.

Robert Neff, MD, discusses how the increasing uptake of HPV vaccination could affect the treatment of patients with cervical cancer.

Vikram C. Gorantla, MD, notes real-world treatment patterns and outcomes with second-line T-DXd vs tucatinib-based therapy in HER2-positive breast cancer.

Robert Neff, MD, discusses how molecular HPV genotyping and testing can be integrated into cervical cancer screening algorithms.

Shubham Pant, MD, discusses data from the phase 3 NAPOLI 3 trial supporting NALIRIFOX as a potent frontline regimen for metastatic pancreatic cancer.

Vikram C. Gorantla, MD, discusses an analysis of T-DXd vs tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer with brain metastases.

Aditya Bardia, MD, MPH, FASCO, discusses the design of the ELEGANT study of elacestrant vs endocrine therapy in high-risk, ER-positive early breast cancer.

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, overviews the phase 3 HARBOR trial evaluating elenestinib in indolent systemic mastocytosis.

Jad Chahoud, MD, MPH, discusses key kidney cancer abstracts to watch at the 2026 ASCO Genitourinary Cancers Symposium.

John O. Mascarenhas, MD, discusses the ongoing investigation of various targeted therapies in myeloproliferative neoplasms.

Manish A. Shah, MD, discusses the PFS benefit with zanidatamab plus chemotherapy with/without tislelizumab in HER2-positive GEA regardless of PD-L1 status.

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, discusses long-term data from avapritinib in advanced systemic mastocytosis from the PATHFINDER trial.